Qiagen (NYSE:QGEN) Earns Buy Rating from Jefferies Financial Group

Qiagen (NYSE:QGEN)‘s stock had its “buy” rating reiterated by Jefferies Financial Group in a report released on Tuesday, MarketBeat Ratings reports. They currently have a $54.00 price target on the stock, up from their previous price target of $42.00. Jefferies Financial Group’s price objective suggests a potential upside of 21.81% from the company’s current price.

QGEN has been the topic of a number of other reports. HSBC cut shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective on the stock. in a research note on Thursday, October 17th. Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research note on Thursday, October 17th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Qiagen currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.15.

Qiagen Stock Performance

Shares of QGEN stock opened at $44.33 on Tuesday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.89 and a current ratio of 2.17. The stock has a market cap of $10.12 billion, a PE ratio of 113.67, a P/E/G ratio of 3.37 and a beta of 0.35. Qiagen has a 1 year low of $39.03 and a 1 year high of $47.44. The stock has a fifty day moving average price of $43.07 and a 200 day moving average price of $43.65.

Hedge Funds Weigh In On Qiagen

Institutional investors have recently added to or reduced their stakes in the business. TD Asset Management Inc purchased a new position in Qiagen during the second quarter worth approximately $2,103,000. Jennison Associates LLC raised its position in shares of Qiagen by 5.0% in the 3rd quarter. Jennison Associates LLC now owns 1,426,392 shares of the company’s stock worth $65,001,000 after buying an additional 68,415 shares during the period. Raymond James & Associates raised its position in shares of Qiagen by 12.7% in the 2nd quarter. Raymond James & Associates now owns 542,453 shares of the company’s stock worth $22,289,000 after buying an additional 61,008 shares during the period. Barings LLC acquired a new position in Qiagen in the second quarter valued at $12,463,000. Finally, Sei Investments Co. grew its position in Qiagen by 19.7% during the second quarter. Sei Investments Co. now owns 1,696,319 shares of the company’s stock valued at $69,702,000 after acquiring an additional 278,930 shares during the period. 70.00% of the stock is currently owned by institutional investors and hedge funds.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.